Revolutionizing GPCR Therapeutics with Designed Biologics
.png)
.png)
First-Ever Designed GPCR Modulators — And Just Getting Started
Our scientific foundation builds on the groundbreaking work of our co-founder, Nobel Laureate Dr. David Baker, and co-founders from his lab at the Institute for Protein Design at the University of Washington and from the BioInnovation Institute in Copenhagen.
.png)
.png)
.png)
Together, we achieved the first-ever de novo design of functional miniproteins, including GPCR agonists and antagonists with structures validated for both function and atomic-level accuracy, and invented high-throughput screening technologies for GPCRs that operate in the native membrane environment, circumventing the need for receptor mutations or solubilization.
.png)
These innovations represent a step change in GPCR-targeted drug discovery. Skape Bio was founded to unite generative protein design, native receptor biology, and scalable in-cell screening into a single platform, unlocking GPCRs and other challenging drug targets that have remained out of reach with traditional approaches.
.png)
.png)
Revolutionizing GCPR drug discovery
Our cutting-edge AI-platform integrates deep evolutionary insights with advanced protein design methodologies tailored specifically for integral membrane proteins, generating molecules with exceptional developability and function. Our proprietary experimental platform enables high-throughput screening of protein designs directly in human cells at massive scale.
No need for target solubilization
Successful delivery of novel agonists and antagonists
Unlocks previously inaccessible GPCRs
Broad applicability across GPCR families
Our Team
We have assembled a tightly integrated team of scientists and engineers with deep expertise in protein design, molecular biology, microscopy and pharmacology. Together under one roof, we are building a next-generation drug discovery platform to unlock GPCRs and other challenging targets through functional miniproteins.
Board of Directors
David Baker, PhD
Board Observer &
Co-Founder
Lance Stewart, PhD MBA
Board Chair &
Co-Founder
Henrik Stage
Board Member &
Co-Founder
Bryan White
Board Member &
Co-Founder
Advisors
Chris Tate, PhD
MRC-LMB
GPCR structure signalling
Bryan Roth
Professor GPCR structure & pharmacology
Malcolm Weir, PhD
Former CEO, Nxera (Heptares)
GPCR therapeutic area
David Younger, PhD
A-Alpha Bio (IPD) Platform company development
Mark Gurney, PhD MBA
deCODE Genetics & Tetra Tx.
Business, strategy
Mette Rosenkilde, PhD
Professor
GPCR Pharmacology
David Feldman, PhD
Co-Founder
High-Throughput methods
David Kim, PhD
Co-Founder
Protein Design
Edin Muratspahic, PhD
Co-Founder
GPCR pharmacology
Investors
Partnering
.png)
.png)
We forge early-stage partnerships to tackle challenging GPCR targets with high therapeutic potential. Our proprietary platform enables the design of functional miniproteins that achieve precise receptor modulation, empowering our partners to pursue differentiated and previously unreachable therapeutic strategies.
Learn more about opportunities
BIOEQUITY | MAY 13, 2025
Skape Bio Engages Investors at BioEquity 2025 in Bruges
CEO Christoffer Norn and Board Chair Lance Stewart showcase platform for next-gen miniprotein therapeutics
BIOEUROPE | MARCH 2025
Skape Bio Showcases AI-Designed Biologics for GPCRs at BioEurope 2025 in Milan
Company joins industry leaders at BioEurope to present innovations in AI-powered drug discovery
Careers
At Skape Bio, we’re designing the future of GPCR therapeutics from first principles. Our team combines cutting-edge protein design, high-throughput screening, and deep biological insight to unlock targets that were once considered out of reach.
We’re based in Copenhagen and are always looking for exceptional scientists, engineers, and builders who are driven by curiosity and motivated to make an impact.
If you’re excited by the idea of creating de novo designed proteins that could reshape drug discovery, we’d love to hear from you.
Photo by Bio Innovation Institute